The startup allows companies to use multiple AI models without locking themselves into enterprise plans.
Cohort inclusion required two neuropsychological evaluations ≥1 year apart, stable DMT ≥3 months, and relapse-/steroid-free status, alongside EDSS scoring and standardized Brief Repeatable Battery ...
NEW YORK--(BUSINESS WIRE)--Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the publication of a new multi-domain model for capturing functional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results